Roche reports a strong start in 2019 and raises the outlook for the full-year

Group sales increase 8% at constant exchange rates and 9% in Swiss francs
Pharmaceuticals Division sales up 10%, driven mainly by Ocrevus, Perjeta, Hemlibra and Tecentriq
Diagnostics Division sales grow 1%, with Molecular Diagnostics as main contributor

Investors
Investor update

Inside Roche

All

Dr-Bobby-Green-in-clinic-at-Florida-Cancer-Specialists-740

Published on: 17 April 2019

Getting closer to cancer research's holy grail

Tags: Science, Innovation, Personalised Healthcare

phc_370x208

Published on: 17 April 2019

Personalised Healthcare

Tags: Personalised Healthcare

WHD-teaser-2019-04-15-740

Published on: 17 April 2019

Measuring what matters

Tags: People, Science, Culture, Innovation, Society, Patients

fighting-the-battle

Published on: 17 April 2019

Small cell, big difference

impact-of-progression-in-multiple-sclerosis-740

Published on: 29 March 2019

Exposing the impact of progression in multiple sclerosis

balance-for-better-740

Published on: 6 March 2019

Balance for better

Tags: People, Culture

Rare disease banner 740

Published on: 28 February 2019

Roche in rare diseases

Tags: Science, Patients

Roche_AR2018_Image_740x416

Published on: 13 February 2019

Annual Report 2018 Highlights